24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Diabetes
Resources
Basic InformationLatest News
Animal Tests Point to Possible Path to Ultrafast InsulinSigns of Developing Adult Diabetes Seen as Early as Age 8: StudyDoes COVID-19 Trigger New Cases of Diabetes?Telehealth Programs Improve Blood Sugar for Rural Americans With DiabetesContinuous Glucose Monitors Help With Type 1 Diabetes at Any AgeCost of Type 1 Diabetes: $2,500 a Year With Insurance1 in 10 Hospitalized COVID-19 Patients With Diabetes Dies: StudyWhite House Announces Plan for Medicare Recipients to Get Insulin at $35 Per MonthLost Pregnancies, Diabetes May Be LinkedType 2 Diabetes Linked to Worse Mental Outcomes After StrokeSleep Apnea Tied to Raised Diabetes Risk in Black AmericansHeart Attacks, Strokes Are Declining Among People With DiabetesCould Your Contact Lenses Track, Treat Your Diabetes?AHA News: Managing Diabetes Risk in Hispanic, Asian CommunitiesObesity Is Biggest Type 2 Diabetes Risk FactorAHA News: Understanding the Risky Combination of Diabetes and the CoronavirusWhy Is Coronavirus a Bigger Worry for People With Diabetes?What People With Type 1 Diabetes Need to Know About COVID-19Family Ties Help Young Adults With Type 1 Diabetes FlourishPatch Pump Device Could Offer Cheaper Insulin DeliveryCan AI Predict Who Will Develop Diabetes?Blood Sugar Control May Aid Stroke Recovery in Diabetes PatientsBacteria May Be a Player in Diabetes Among Very ObeseNew Tool Helps Muslims With Diabetes Manage Blood Sugar During Ramadan FastWant to Help Keep Diabetes at Bay? Brush & FlossDiabetes Among U.S. Young, Especially Asians, Continues to ClimbDrug Duo Speeds Regeneration of Key Cells Lost in DiabetesMedicare Could Save Billions If Allowed to Negotiate Insulin PricesAt the Barbershop, a Trim -- and a Diabetes ScreeningCertain Diabetes Meds May Lower Gout Risk, TooBig Advances Made Against Diabetes in 2019CDC Study Breaks Down Diabetes Risk for Hispanic, Asian SubgroupsFDA Authorizes Marketing of Automated Insulin Dosing ControllerDo Processed Foods Up Your Type 2 Diabetes Risk?Changing Timing, Frequency of Meals May Help With Diabetes'Diabetes Burnout' Is Real, Here's How to CopeAs Diabetes Costs Soar, Many Turn to Black Market for HelpFDA Testing Levels of Carcinogen in Diabetes Drug MetforminMom-to-Be's Diabetes May Up Odds of Heart Disease in Her KidsPrediabetes Now Common Among Teens, Young AdultsHeart Attack at 44 Helped Her Realize Diabetes' DangersDiabetes Tougher on Women's HeartsDiabetes Technology Often Priced Out of ReachSupplements Don't Prevent Kidney Disease in Type 2 DiabeticsWhy Are Insulin Prices Still So High for U.S. Patients?Health Tip: Snacks for People With DiabetesHigh-Tech Pacifier Might Monitor Baby's Blood SugarThe Exercise Effect and PrediabetesNext-Gen Artificial Pancreas Boosts Blood Sugar ControlHurricanes Raise Death Risk for Older Diabetics, Even Years Later
Links
Related Topics

Medical Disorders

Why Are Insulin Prices Still So High for U.S. Patients?

HealthDay News
by By Serena Gordon
HealthDay Reporter
Updated: Nov 7th 2019

new article illustration

WEDNESDAY, Nov. 6, 2019 (HealthDay News) -- Nearly a century ago, Dr. Frederick Banting discovered lifesaving insulin, but skyrocketing prices are putting the drug out of reach for many he sought to help.

The average price of insulin nearly tripled between 2002 and 2013 in the United States, according to an American Diabetes Association study. Yet other countries pay significantly less. In fact, Americans pay more than 10 times as much for insulin as Canadians do, according to a commentary published in the Nov. 7 issue of the New England Journal of Medicine.

"Insulin is a flashpoint in the drug-pricing debate, and it's still an ongoing issue. It's a relatively unique product that will require special solutions because so many people rely on it to ensure they can live day to day," said commentary co-author Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical School.

The current costs would no doubt disappoint Canadian scientist Banting. In the 1920s he and his team members sold the patent for insulin to the University of Toronto for $1 each. They felt that insulin was such an important medication that it needed to be affordable, according to the NEJM commentary.

"Insulin does not belong to me, it belongs to the world," Banting once said.

Today, more than 7 million people in America use insulin. People with type 1 diabetes make little to no insulin, so they must replace the lost hormone through injections or via a tiny tube inserted under the skin and attached to a pump. People with type 2 diabetes still make insulin, but often not enough. Some people with type 2 diabetes also need to use insulin.

Manufacturers have upper hand

Kesselheim and colleague Dr. Michael Fralick wrote that there are two main reasons why insulin is so expensive now. One is that U.S. laws let pharmaceutical manufacturers set their own prices and raise them without limit.

The second reason, the authors noted, is that there isn't significant competition in the U.S. insulin market. Price competition typically comes from the introduction of a generic drug that directly competes with a branded product.

But the authors said that current insulin makers have blocked the entry to such products by getting new patents based on things such as a new delivery device.

Kesselheim also noted that "insulin is a slightly more complicated molecule," which makes developing a generic version more challenging.

He said that the makers of insulin have begun selling "authorized generics" of their brand-name products. Eli Lilly and Co. is selling a generic version of their branded insulin Humalog for 50% less than the brand-name product, according to Greg Kueterman, a company spokesperson.

Kueterman added that Eli Lilly doesn't currently have any patent-protected insulins. He said the company is also capping prices at the pharmacy for people with commercial health insurance, and increasing eligibility for free insulin for those with very low incomes.

Quinn Nystrom, 33, from Baxter, Minn., has type 1 diabetes. She's been working with local and federal elected officials to improve insulin access and affordability.

She's helped lead three bus trips to Canada so people could buy more affordable insulin. The same vial of insulin that she pays $340 for in the United States costs $30 in Canada, she said.

"A single vial of current analog insulin costs around $3 to $6 to make. There is no reason for that price difference between the U.S. and Canada, other than that Canada holds down their drug prices with legislation," Nystrom said.

But she doesn't see trips to Canada as a solution to the insulin pricing problem.

"These trips to Canada are like putting a Band-Aid on a gunshot wound," Nystrom said.

Nystrom has become so frustrated by inaction on the insulin pricing issue and the price of drugs in general that she's decided to run for U.S. Congress, and has pledged that she won't be taking any drug or insurance company money for her campaign.

She pointed out that insulin pricing affects everyone, diabetic or not. "If someone can't afford insulin, they end up rationing the insulin they have," Nystrom said. That leads to complications that send people to the hospital, which ends up costing far more than the insulin would have. "This affects everyone's pocketbook," she added.

Reform efforts in the works

Some politicians have introduced legislation to help contain the cost of insulin, with varying success. Officials in Colorado passed a bill that limits out-of-pocket copays to no more than $100 a month for insulin.

Several federal bills have also been introduced, including by presidential candidate Elizabeth Warren. "Warren's bill would develop a government manufacturing facility to provide lower-cost insulin," Kesselheim said.

Cigna, a large private insurer, has limited monthly copayments for insulin to $25.

Holly Campbell, a spokesperson for PhRMA, a pharmaceutical manufacturer trade association, said, "Dramatic improvements in how we treat diabetes have transformed the lives of patients, but this innovation isn't enough if patients can't afford their insulin and other medicines at the pharmacy."

She said that insulin prices after discounts and rebates have gone down in recent years, but that these negotiated savings aren't always directly shared with consumers. Campbell said incentives offered in the supply chain need to be changed so that those rebates and discounts lower prices for the consumer.

More information

Learn more about insulin pricing from the Endocrine Society.